tqb3702
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05610202)
Timeline
Indications
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859931 | Phase 2 | Mar 31, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06566586 | Phase 2 | Nov 6, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06448273 | Phase 1 | Jul 19, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06211751 | Phase 1 | Jan 31, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05610202 | Phase 1 | Nov 30, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 5 | 5 | 2 | 2022 |
1 organizations
Page 1 / 1